Elan Says It Has Fixed The Biogen Breach, And Gives J&J a $115 Million Discount

The three-way drama heads toward a resolution -- if Biogen Idec accepts Elan's moves.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet